{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:31:23Z","timestamp":1789011083157,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>von Willebrand disease (VWD) is the common bleeding disorder with a clinically relevant bleeding prevalence of 1:10,000. von Willebrand disease patients lack both von Willebrand factor (VWF) and factor VIII (FVIII), which are critical for normal haemostasis. The conventional treatment for VWD includes desmopressin and replacement therapy with plasma derived FVIII with VWF concentrates or recombinant VWF. Development of alloantibodies is a rare occurrence, there is a paucity in the literature of treatment modalities in these patients. Not many reports are available in literature on the efficacy of emicizumab in VWD patients with or without alloantibodies to VWF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To do systematic review of literature on emicizumab in VWD and report our experience of emicizumab in two patients of VWD<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used electronic search engines till May 2021 in \u2018Google scholar\u2019 and \u2018PubMed\u2019, to collect the case reports or case series on use of emicizumab for management of VWD. Two of our severe VWD patients were successfully treated with emicizumab. A systematic review was performed and the results discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The electronic search revealed six case reports using emicizumab for treatment of VWD. Two were in vitro studies and four in patients with VWD type 3 disease. In vitro studies and in VWD patients on emicizumab, showed improvement in thrombin generation and fibrin formation. Among four patients, three had alloantibodies to VWD and one was negative. All these patients were treated with emicizumab for 6\u201312\u00a0m. After starting emicizumab, none of them had spontaneous bleeding requiring treatment. During treatment with emicizumab, one patient had trauma\u2010associated soft tissue hematoma, which was treated with rFVIIa and another patient had bleeding following dental exfoliation treated with Humate P. We treated two of our VWD patients one with and one without inhibitors with emicizumab after failure of other therapies. Both the patients showed marked improvement and continued to remain well and free of bleeding episodes. None of the patients had any thrombosis or thrombotic microangiopathy (TMA) during treatment with emicizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, this review supports the safety and efficacy of emicizumab in type 3 VWD patients with or without alloantibodies. Further large studies are required to confirm the safety and efficacy of emicizumab in VWD.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14491","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T07:25:53Z","timestamp":1641885953000},"page":"286-291","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-866X","authenticated-orcid":false,"given":"Chandrakala","family":"Shanmukhaiah","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology Seth G.S. Medical College and KEM Hospital Parel  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Jijina","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Seth G.S. Medical College and KEM Hospital Parel  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kannan","sequence":"additional","affiliation":[{"name":"Department of Haematology Sahyadri Specialty Hospitals  Pune India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda G","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Dentistry Seth G.S. Medical College and KEM Hospital Parel  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-5256","authenticated-orcid":false,"given":"Bipin","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"ICMR\u2010 National Institute of Immunohaematology  13th floor, MS building, KEM Hospital Campus, Parel Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh V","family":"Khuba","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Seth G.S. Medical College and KEM Hospital Parel  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Seth G.S. Medical College and KEM Hospital Parel  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Haematology Sahyadri Specialty Hospitals  Pune India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Phatale","sequence":"additional","affiliation":[{"name":"Department of Haematology Sahyadri Specialty Hospitals  Pune India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Apte","sequence":"additional","affiliation":[{"name":"Department of Haematology Sahyadri Specialty Hospitals  Pune India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613992"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02966.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198207083070221"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613992"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003265"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.71.8.2937"},{"key":"e_1_2_10_10_1","first-page":"109","article-title":"Antibodies to factor VIII\u2010von Willebrand factor in congenital and acquired von Willebrand's disease","volume":"150","author":"Mannucci PM","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462085"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-0331-2_7"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"issue":"1","key":"e_1_2_10_14_1","first-page":"1071","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study","volume":"130","author":"Mancuso ME","year":"2017","journal-title":"Blood"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.85.85"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.86.86"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102530"},{"key":"e_1_2_10_19_1","article-title":"Effectiveness of emicizumab in preventing life\u2010threatening bleeding complications in type 3 von Willebrand disease with inhibitors: a paediatric report","author":"Cefalo MG","year":"2020","journal-title":"Haemophilia"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.11.026"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14272"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000656"},{"issue":"1","key":"e_1_2_10_23_1","article-title":"Treatment with emicizumab leads to clinical improvement in a type 3 von Willebrand disease patient with inhibitor suffering from a left ankle arthropathy [abstract]","volume":"4","author":"Sigaud M","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11460"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:42:23Z","timestamp":1692978143000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/hae.14491"],"URL":"https:\/\/doi.org\/10.1111\/hae.14491","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"2021-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}